Tufts University

VantAI Appoints John Cuozzo as Senior Vice President, Head of Drug Discovery

Retrieved on: 
水曜日, 5月 8, 2024
Health, Technology, Health Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, Machine learning, Tufts University, Doctor of Philosophy, Research, IND, Drug discovery, SVP, Media, Drug development, Head, MIT, Pharmaceutical industry

VantAI, a leader in generative AI and drug discovery, today announced the appointment of John Cuozzo, PhD as SVP, Head of Drug Discovery.

Key Points: 
  • VantAI, a leader in generative AI and drug discovery, today announced the appointment of John Cuozzo, PhD as SVP, Head of Drug Discovery.
  • Cuozzo is an experienced scientific leader with a strong track record of building novel discovery platforms and leading successful drug discovery programs.
  • Prior to Relay, Cuozzo was Head of Drug Discovery at ZebiAI, a company that applied massive DNA-encoded library datasets to power machine learning for drug discovery.
  • As Head of Drug Discovery, Cuozzo will lead drug discovery strategy and technology development to expand the company's research capabilities.

Top OECD Negotiator, Michael Plowgian, Rejoins KPMG LLP

Retrieved on: 
火曜日, 4月 16, 2024
Pillar, Negotiation, Harvard Law School, Economy, Denison University, KPMG, Organization, Treasury, Tufts University, Diplomacy, Human, Legislation, KPMG LLP, OECD, Renewable energy

New York, New York--(Newsfile Corp. - April 16, 2024) - KPMG LLP, the U.S. audit, tax, and advisory firm, today announced that Michael Plowgian, a leading voice in international tax policy, has rejoined the firm as a principal in Washington National Tax.

Key Points: 
  • New York, New York--(Newsfile Corp. - April 16, 2024) - KPMG LLP, the U.S. audit, tax, and advisory firm, today announced that Michael Plowgian, a leading voice in international tax policy, has rejoined the firm as a principal in Washington National Tax.
  • He will also serve as the International Tax Policy Lead for the Americas and on the Global Policy Leadership Team.
  • "Michael's first-hand experience negotiating at the OECD will be invaluable to our multinational clients grappling with its implementation," said Rema Serafi (@remaserafi), Vice Chair - Tax, KPMG LLP.
  • "The new international tax landscape is extraordinarily complex, with far-reaching impacts on companies' tax positions, compliance, operations and more," said Danielle Rolfes , partner in charge - Washington National Tax, KPMG LLP.

Nourishing Tomorrow: How 'Food is Medicine' Advances Food Retailing and Positive Outcomes for Nutrition Responsive Health Conditions

Retrieved on: 
金曜日, 4月 26, 2024
Software, General Health, Health, Supermarket, Technology, Food, Beverage, Fitness & Nutrition, Retail, Walmart, Summit, Health equity, Blood pressure, Instacart, Love, Tufts University, Partnership, Weight loss, Transport, Medicine, Science, PCP, Trust, Nutrition, Quality of life, Organization

At the Summit, Co-Founder and President of Good Measures, Stefany Shaheen, joined colleagues from Kroger, Instacart, Season Health, and Walmart on a panel titled "Research Advances in Food Retailing."

Key Points: 
  • At the Summit, Co-Founder and President of Good Measures, Stefany Shaheen, joined colleagues from Kroger, Instacart, Season Health, and Walmart on a panel titled "Research Advances in Food Retailing."
  • Together, they explored innovations in food retailing to advance the accessibility of food prescription programs and other approaches by offering programs in a personalized, culturally relevant manner.
  • Through our partnerships, we’re helping build personalized food prescription programs, tailored to individual health conditions," explained Sarah Mastrorocco, VP & GM of Instacart Health.
  • By prioritizing accessibility, cultural relevance, and nutrition intervention, these initiatives are not only improving health outcomes, but also empowering people to make healthier choices.

Morphoceuticals Names Jim Jenson, PhD as CEO to Advance AI-Guided Regenerative Medicine Technology

Retrieved on: 
木曜日, 4月 18, 2024
Biotechnology, Technology, Other Health, Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Artificial Intelligence, Genetics, Science, School, Noetics, Macalester College, Roche, Biochemistry, Map, Tufts University, Doctor of Philosophy, DRS, Electron, Cornell University, Therapy, Novo Nordisk, Regenerative medicine, Inc., Regeneration, Management

Morphoceuticals Inc. , a new biotechnology company pioneering AI-guided electroceuticals for tissue repair and organ regeneration, today announced the appointment of veteran biotech executive Jim Jenson, PhD, as CEO.

Key Points: 
  • Morphoceuticals Inc. , a new biotechnology company pioneering AI-guided electroceuticals for tissue repair and organ regeneration, today announced the appointment of veteran biotech executive Jim Jenson, PhD, as CEO.
  • Jenson joins a growing team and will lead the company as it advances its novel regenerative medicine technology platform.
  • Jenson has more than 35 years of experience in the biotech and pharmaceutical industries, as both an entrepreneur and executive leader.
  • He most recently served as the Co-founder and CEO of CytoSite Biopharma Inc., which develops new technology to predict and monitor responses to immuno-oncology therapy.

AMD Lead Independent Director Nora Denzel and Best Buy Board Chair-Elect David Kenny to Co-Chair the 2024 NACD Blue Ribbon Commission on Board Oversight of Technology

Retrieved on: 
火曜日, 4月 16, 2024
NACD, City, Toyota, Vanguard, Tufts University, Pentair, Business, Intelligence, Harvard Business School, Chairperson, SIPA, The Weather Company, CSX Corporation, HPE, AMD, Trust, Asurion, Nashville Electric Service, Sally Beauty Holdings, General Atlantic, Blue-ribbon committee, CIO, Head, Weather Underground (weather service), RET, ServiceNow, United States Air Force, International, Consumer, General counsel, Blockchain, Advisory board, Research, Artificial intelligence, Commission, Drexel University, World Economic Forum, Booking Holdings, Former, UMB, Akamai Technologies, Organization, Weather, Public affairs, UMB Financial Corporation, Quest Diagnostics, Gen, Senior, Intuit, Innovation Hub, Growth, IBM, Management

WASHINGTON, April 16, 2024 /PRNewswire/ -- NACD today announced it has appointed a commission to examine board oversight of technology, prompted in part by the emergence of disruptive technologies like generative artificial intelligence which are impacting all business operations. The 2024 NACD Blue Ribbon Commission will be spearheaded by the following co-chairs:

Key Points: 
  • The 2024 NACD Blue Ribbon Commission will be spearheaded by the following co-chairs:
    Nora Denzel , NACD.DC™, Lead Independent Director, Advanced Micro Devices, Director, Gen Digital and NACD, and Former C-suite Technology Executive at Intuit, HPE and IBM.
  • David Kenny , Board Chair-Elect, Best Buy, Executive Chair, Nielsen and former CEO of Digitas, Akamai, Publicis, The Weather Company and Nielsen.
  • Directors cited the increasing pace of technological change as a top priority for 2024 in the most recent NACD Directors Outlook .
  • David Kenny , Board Chair-Elect, Best Buy; Executive Chair, Nielsen; and former CEO of Digitas, Akamai, Publicis, The Weather Company and Nielsen.

Edward Hall Nominated to Join the Board of Directors of TPI Composites, Inc.

Retrieved on: 
火曜日, 4月 9, 2024
Electricity, General Cable, Tufts University, Mechanical engineering, Pearson Yachts, AES Corporation, Wind, Wellesley Municipal Light Plant, TPI

SCOTTSDALE, Ariz., April 09, 2024 (GLOBE NEWSWIRE) -- TPI Composites, Inc. (TPI) (Nasdaq: TPIC) announced today that Edward “Ned” Hall has been nominated to join its board of directors, and if elected, will become a director, effective immediately upon the conclusion of TPI’s annual meeting of stockholders on May 29, 2024.

Key Points: 
  • SCOTTSDALE, Ariz., April 09, 2024 (GLOBE NEWSWIRE) -- TPI Composites, Inc. (TPI) (Nasdaq: TPIC) announced today that Edward “Ned” Hall has been nominated to join its board of directors, and if elected, will become a director, effective immediately upon the conclusion of TPI’s annual meeting of stockholders on May 29, 2024.
  • TPI also announced that Philip Deutch and Linda Hudson were retiring from TPI’s Board of Directors, effective upon the conclusion of TPI’s annual meeting of stockholders on May 29, 2024.
  • Mr. Deutch and Ms. Hudson have served as directors since 2007 and 2020, respectively.
  • “We are excited to have Ned join our board,” said Bill Siwek, TPI’s President and CEO.

HashiCorp Promotes Christine Centa to Chief People Officer

Retrieved on: 
火曜日, 3月 26, 2024
HR, Culture, Pivotal Software, HashiCorp, Caesars Entertainment, Tufts University, CPO, SAN, Diversity, Acquisition, MBA, Marketing, Centa, Workplace, HCP, Babson College, Management

SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- HashiCorp, Inc. (NASDAQ: HCP), a leader in multi-cloud infrastructure automation software, today announced that Christine Centa has been promoted from Vice President of Total Rewards to Chief People Officer (CPO).

Key Points: 
  • SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- HashiCorp, Inc. (NASDAQ: HCP), a leader in multi-cloud infrastructure automation software, today announced that Christine Centa has been promoted from Vice President of Total Rewards to Chief People Officer (CPO).
  • “Christine is an outstanding leader on the People team who has made significant contributions since joining HashiCorp in 2020,” said Dave McJannet, CEO, HashiCorp.
  • “I’m honored to take on the Chief People Officer role at HashiCorp and continue building our people practices to create an inclusive, equitable, and engaging employee experience for our global workforce,” said Centa.
  • As HashiCorp continues to grow, my work will be focused on ensuring employees are growing alongside HashiCorp.”

State Street’s Research Team Announces Academic Partnership with Daniel Drezner of The Fletcher School, expanding Markets Research Capabilities in Arena of Geopolitical Risk

Retrieved on: 
月曜日, 4月 8, 2024
Finance, Consulting, Professional Services, Public Policy, Government, Other Policy Issues, Department of the Treasury, Conference, Politics, University, The Washington Post, Data science, Tufts University, Foreign Affairs, Partnership, Risk, STT, Social media, Research, State Street Corporation, Publication, Language, Book, State Street, The Wall Street Journal, State

Mr. Drezner will partner with State Street Associates, the firm’s hub for partnerships with academics and fintech start-ups, which powers its award-winning markets research platform for foreign exchange trading, equities trading, and securities lending clients.

Key Points: 
  • Mr. Drezner will partner with State Street Associates, the firm’s hub for partnerships with academics and fintech start-ups, which powers its award-winning markets research platform for foreign exchange trading, equities trading, and securities lending clients.
  • “Our clients are increasingly contemplating the risk of ongoing and potential conflicts around the world as well as several high-stakes, national elections."
  • "I am honoured to collaborate with State Street Associates as its newest academic partner,” said Professor Drezner.
  • As part of his engagement with State Street, Professor Drezner will be a featured speaker at the 2024 Markets & Financing Research Conference.

Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
月曜日, 3月 25, 2024
Tax, Growth, Tufts University, Patient, Extracellular matrix, Classification, Sale, Acquisition, Nature, Adjustment, SMTI, Infection, Depreciation, GAAP, Peptide

Zach Fleming, Sanara's CEO, stated, “During 2023, the Sanara team achieved several key strategic and operational milestones that position the Company for continued strong growth in 2024.

Key Points: 
  • Zach Fleming, Sanara's CEO, stated, “During 2023, the Sanara team achieved several key strategic and operational milestones that position the Company for continued strong growth in 2024.
  • The Company’s products were contracted or approved to be sold in more than 3,000 hospitals/ambulatory surgery centers as of December 31, 2023.
  • In October 2023, Sanara recorded its first sale of ALLOCYTE® Plus, a human cell and tissue-based product.
  • In November 2023, Sanara announced the publication of a retrospective study involving 5,335 patients.

IDRx Appoints David P. Kerstein, M.D., as Chief Medical Officer

Retrieved on: 
水曜日, 3月 27, 2024
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Sumitomo Pharma, Takeda Pharmaceutical Company, Tufts University, Patient, Therapy, Takeda, GIST, ARIAD Pharmaceuticals, Pharmaceutical industry

IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today announced the appointment of David P. Kerstein, M.D., as Chief Medical Officer.

Key Points: 
  • IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today announced the appointment of David P. Kerstein, M.D., as Chief Medical Officer.
  • Dr. Kerstein brings to IDRx deep experience in early- and late-stage oncology drug development, including multiple precision oncology medicines.
  • He joins the founding IDRx R&D leadership team of Jessica Christo, Chief Development Operations Officer, and Vivek (Vic) Kadambi, Ph.D., Chief Product Development Officer.
  • Before Theseus, Dr. Kerstein served as Chief Medical Officer of Anchiano Therapeutics Ltd.